282 results on '"Di Lorenzo, Emilio"'
Search Results
102. Paclitaxel-eluting versus bare metal stents in primary PCI: a pooled patient-level meta-analysis of randomized trials
- Author
-
De Luca, Giuseppe, primary, Dirksen, Maurits T., additional, Kelbæk, Henning, additional, Thuesen, Leif, additional, Vink, Marteen A., additional, Kaiser, Christoph, additional, Chechi, Tania, additional, Spaziani, Gaia, additional, Di Lorenzo, Emilio, additional, Suryapranata, Harry, additional, and Stone, Gregg W., additional
- Published
- 2014
- Full Text
- View/download PDF
103. Gender-related differences in outcome after BMS or DES implantation in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: Insights from the DESERT cooperation
- Author
-
De Luca, Giuseppe, primary, Verdoia, Monica, additional, Dirksen, Maurits T., additional, Spaulding, Christian, additional, Kelbæk, Henning, additional, Schalij, Martin, additional, Thuesen, Leif, additional, Hoeven, Bas van der, additional, Vink, Marteen A., additional, Kaiser, Christoph, additional, Musto, Carmine, additional, Chechi, Tania, additional, Spaziani, Gaia, additional, Diaz de la Llera, Luis Salvador, additional, Pasceri, Vincenzo, additional, Di Lorenzo, Emilio, additional, Violini, Roberto, additional, Suryapranata, Harry, additional, and Stone, Gregg W., additional
- Published
- 2013
- Full Text
- View/download PDF
104. Virtual Structural Monitoring of Wind Turbines Using Operational Modal Analysis Techniques
- Author
-
di Lorenzo, Emilio, primary, Manzato, Simone, additional, Peeters, Bart, additional, and van der Auweraer, Herman, additional
- Published
- 2013
- Full Text
- View/download PDF
105. Dual antiplatelet therapy duration
- Author
-
Musumeci, Giuseppe, primary, Di Lorenzo, Emilio, additional, and Valgimigli, Marco, additional
- Published
- 2011
- Full Text
- View/download PDF
106. Addition of atropine to submaximal exercise stress testing in patients evaluated for suspected ischaemia with SPECT imaging: a randomized, placebo-controlled trial
- Author
-
Manganelli, Fiore, primary, Spadafora, Marco, additional, Varrella, Paola, additional, Peluso, Giuseppina, additional, Sauro, Rosario, additional, Di Lorenzo, Emilio, additional, Rosato, Giuseppe, additional, Daniele, Stefania, additional, and Cuocolo, Alberto, additional
- Published
- 2010
- Full Text
- View/download PDF
107. Osborn waves in severe accidental hypothermia secondary to prolonged immobilization and malnutrition
- Author
-
Rotondi, Francesco, primary, Manganelli, Fiore, additional, Candelmo, Fiore, additional, Marino, Luciano, additional, Di Lorenzo, Emilio, additional, Alfano, Ferdinando, additional, Stanco, Giovanni, additional, and Rosato, Giuseppe, additional
- Published
- 2010
- Full Text
- View/download PDF
108. Impact of diabetes on long-term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIb–IIIa inhibitors and BMS or DES
- Author
-
De Luca, Giuseppe, primary, Sauro, Rosario, additional, Varricchio, Attilio, additional, Capasso, Michele, additional, Lanzillo, Tonino, additional, Manganelli, Fiore, additional, Mariello, Ciro, additional, Siano, Francesco, additional, Carbone, Giannignazio, additional, Pagliuca, Maria Rosaria, additional, Rosato, Giuseppe, additional, and Di Lorenzo, Emilio, additional
- Published
- 2009
- Full Text
- View/download PDF
109. Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor Simvastatin Prevents Cardiac Hypertrophy Induced by Pressure Overload and Inhibits p21 ras Activation
- Author
-
Indolfi, Ciro, primary, Di Lorenzo, Emilio, additional, Perrino, Cinzia, additional, Stingone, Angela Maria, additional, Curcio, Antonio, additional, Torella, Daniele, additional, Cittadini, Antonello, additional, Cardone, Luca, additional, Coppola, Carmela, additional, Cavuto, Luigi, additional, Arcucci, Oreste, additional, Sacca, Luigi, additional, Avvedimento, Enrico Vittorio, additional, and Chiariello, Massimo, additional
- Published
- 2002
- Full Text
- View/download PDF
110. Effects of Balloon Injury on Neointimal Hyperplasia in Streptozotocin-Induced Diabetes and in Hyperinsulinemic Nondiabetic Pancreatic Islet–Transplanted Rats
- Author
-
Indolfi, Ciro, primary, Torella, Daniele, additional, Cavuto, Luigi, additional, Davalli, Alberto M., additional, Coppola, Carmela, additional, Esposito, Giovanni, additional, Carriero, Mariolina V., additional, Rapacciuolo, Antonio, additional, Di Lorenzo, Emilio, additional, Stabile, Eugenio, additional, Perrino, Cinzia, additional, Chieffo, Alaide, additional, Pardo, Francesco, additional, and Chiariello, Massimo, additional
- Published
- 2001
- Full Text
- View/download PDF
111. Membrane-Bound Protein Kinase A Inhibits Smooth Muscle Cell Proliferation In Vitro and In Vivo by Amplifying cAMP–Protein Kinase A Signals
- Author
-
Indolfi, Ciro, primary, Stabile, Eugenio, additional, Coppola, Carmela, additional, Gallo, Adriana, additional, Perrino, Cinzia, additional, Allevato, Giovanna, additional, Cavuto, Luigi, additional, Torella, Daniele, additional, Di Lorenzo, Emilio, additional, Troncone, Giancarlo, additional, Feliciello, Antonio, additional, Avvedimento, Enrico Vittorio, additional, and Chiariello, Massimo, additional
- Published
- 2001
- Full Text
- View/download PDF
112. 8-Chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo
- Author
-
Indolfi, Ciro, primary, Di Lorenzo, Emilio, additional, Rapacciuolo, Antonio, additional, Stingone, Angela Maria, additional, Stabile, Eugenio, additional, Leccia, Antonio, additional, Torella, Daniele, additional, Caputo, Rosa, additional, Ciardiello, Fortunato, additional, Tortora, Gianpaolo, additional, and Chiariello, Massimo, additional
- Published
- 2000
- Full Text
- View/download PDF
113. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury
- Author
-
Indolfi, Ciro, primary, Cioppa, Angelo, additional, Stabile, Eugenio, additional, Di Lorenzo, Emilio, additional, Esposito, Giovanni, additional, Pisani, Alfonso, additional, Leccia, Antonio, additional, Cavuto, Luigi, additional, Stingone, Angela Maria, additional, Chieffo, Alaide, additional, Capozzolo, Claudia, additional, and Chiariello, Massimo, additional
- Published
- 2000
- Full Text
- View/download PDF
114. Smooth Muscle Cell Proliferation Is Proportional to the Degree of Balloon Injury in a Rat Model of Angioplasty
- Author
-
Indolfi, Ciro, primary, Esposito, Giovanni, additional, Di Lorenzo, Emilio, additional, Rapacciuolo, Antonio, additional, Feliciello, Antonio, additional, Porcellini, Antonio, additional, Avvedimento, Vittorio E., additional, Condorelli, Mario, additional, and Chiariello, Massimo, additional
- Published
- 1995
- Full Text
- View/download PDF
115. Impact of DRG billing system on health budget consumption in percutaneous treatment of mitral valve regurgitation in heart failure
- Author
-
Palmieri, Vittorio, Baldi, Cesare, Di Blasi, Paola E., Citro, Rodolfo, Di Lorenzo, Emilio, Bellino, Elisabetta, Preziuso, Feliciano, Ranaudo, Carlo, Sauro, Rosario, and Rosato, Giuseppe
- Abstract
AbstractObjective:Percutaneous correction of mitral regurgitation (MR) by MitraClip (Abbot Vascular, Abbot Park, Illinois, USA) trans-catheter procedure (MTP) may represent a treatment for an unmet need in heart failure (HF), but with a largely unclear economic impact.Research design and methods:This study estimated the economic impact of the MTP in common practice using the disease-related group (DRG) billing system, duration and average cost per day of hospitalization as main drivers. Life expectancy was estimated based on the Seattle Heart Failure Model. Quality-of-life was derived by standard questionnaires to compute quality-adjusted year-life costs.Results:Over 5535 discharges between 2012–2013, HF as DRG 127 was the main diagnosis in 20, yielding a reimbursement of €3052.00/case; among the DRG 127, MR by ICD-9 coding was found in 12. Duration of hospitalization was longer for DRG 127 with than without MR (9 vs 8 days, p < 0.05). HF in-hospital management generated most frequently deficit, in particular in the presence of MR, due to the high costs of hospitalization, higher than reimbursement. MTP to treat MR allowed DRG 104-related reimbursement of €24,675.00. In a cohort of 34 HF patients treated for MR by MTP, the global budget consumption was 2-fold higher compared to that simulated for those cases medically managed at 2-year follow-up. Extrapolated cost per quality-adjusted-life-years (QALY) for MTP at year-2 follow-up was ∼€16,300.Conclusions:Based on DRG and hospitalization costing estimates, MTP might be cost-effective in selected HF patients with MR suitable for such a specific treatment, granted that those patients have a clinical profile predicting high likelihood of post-procedural clinical stability in sufficiently long follow-up.
- Published
- 2015
- Full Text
- View/download PDF
116. Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.
- Author
-
Di Lorenzo E, Sauro R, Varricchio A, Carbone G, Cortese G, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, De Luca G, Di Lorenzo, Emilio, Sauro, Rosario, Varricchio, Attilio, Carbone, Giannignazio, Cortese, Giuliana, and Capasso, Michele
- Published
- 2009
- Full Text
- View/download PDF
117. Time course, predictors and clinical implications of stent thrombosis following primary angioplasty
- Author
-
De Luca, Giuseppe, Dirksen, Maurits T., Spaulding, Christian, Kelbæk, Henning, Schalij, Martin, Thuesen, Leif, van der Hoeven, Bas, Vink, Marteen A., Kaiser, Christoph, Musto, Carmine, Chechi, Tania, Spaziani, Gaia, de la Llera, Luis Salvador Diaz, Pasceri, Vincenzo, Di Lorenzo, Emilio, Violini, Roberto, Suryapranata, Harry, and Stone, Gregg W.
- Published
- 2013
- Full Text
- View/download PDF
118. Stentsliberadores de fármacos frente a stentsconvencionales en pacientes diabéticos con infarto agudo de miocardio con elevación del segmento ST: un análisis combinado de los datos de pacientes individuales de 7 ensayos aleatorizados
- Author
-
Iijima, Raisuke, Byrne, Robert A., Dibra, Alban, Ndrepepa, Gjin, Spaulding, Christian, Laarman, Gerrit J., Menichelli, Maurizio, Valgimigli, Marco, Di Lorenzo, Emilio, Kaiser, Christoph, Tierala, Ilkka, Mehilli, Julinda, Suttorp, Maarten J., Violini, Roberto, Schömig, Albert, and Kastrati, Adnan
- Abstract
Los resultados obtenidos con los stentsliberadores de fármacos (SLF) en el grupo de pacientes de alto riesgo formado por los pacientes diabéticos con infarto agudo de miocardio con elevación del segmento ST (IAMCEST) tratados con angioplastia primaria no se han estudiado con anterioridad. Nuestro objetivo fue evaluar la eficacia y la seguridad de los SLF en pacientes diabéticos con IAMCEST.
- Published
- 2009
- Full Text
- View/download PDF
119. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction
- Author
-
Kastrati, Adnan, Dibra, Alban, Spaulding, Christian, Laarman, Gerrit J., Menichelli, Maurizio, Valgimigli, Marco, Di Lorenzo, Emilio, Kaiser, Christoph, Tierala, Ilkka, Mehilli, Julinda, Seyfarth, Melchior, Varenne, Olivier, Dirksen, Maurits T., Percoco, Gianfranco, Varricchio, Attilio, Pittl, Undine, Syvänne, Mikko, Suttorp, Maarten J., Violini, Roberto, Schömig, Albert, Kastrati, Adnan, Dibra, Alban, Spaulding, Christian, Laarman, Gerrit J., Menichelli, Maurizio, Valgimigli, Marco, Di Lorenzo, Emilio, Kaiser, Christoph, Tierala, Ilkka, Mehilli, Julinda, Seyfarth, Melchior, Varenne, Olivier, Dirksen, Maurits T., Percoco, Gianfranco, Varricchio, Attilio, Pittl, Undine, Syvänne, Mikko, Suttorp, Maarten J., Violini, Roberto, and Schömig, Albert
- Abstract
Aims To compare the efficacy and safety of drug-eluting stents vs. bare-metal stents in patients with acute ST-segment elevation myocardial infarction. Methods and results We performed a meta-analysis of eight randomized trials comparing drug-eluting stents (sirolimus-eluting or paclitaxel-eluting stents) with bare-metal stents in 2786 patients with acute ST-segment elevation myocardial infarction. All patients were followed up for a mean of 12.0-24.2 months. Individual data were available for seven trials with 2476 patients. The primary efficacy endpoint was the need for reintervention (target lesion revascularization). The primary safety endpoint was stent thrombosis. Other outcomes of interest were death and recurrent myocardial infarction. Drug-eluting stents significantly reduced the risk of reintervention, hazard ratio of 0.38 (95% CI, 0.29-0.50), P < 0.001. The overall risk of stent thrombosis: hazard ratio of 0.80 (95% CI, 0.46-1.39), P = 0.43; death: hazard ratio of 0.76 (95% CI, 0.53-1.10), P = 0.14; and recurrent myocardial infarction: hazard ratio of 0.72 (95% CI, 0.48-1.08, P = 0.11) was not significantly different for patients receiving drug-eluting stents vs. bare-metal stents. Conclusion The use of drug-eluting stents in patients with acute ST-segment elevation myocardial infarction is safe and improves clinical outcomes by reducing the risk of reintervention compared with bare-metal stents
120. Periodic administration of levosimendan as a bridge to transplant : Potiusque sero quam nunquam
- Author
-
Masarone, Daniele, Falco, Luigi, Caiazzo, Angelo, Marra, Claudio, and di Lorenzo, Emilio
- Full Text
- View/download PDF
121. Population Trends in Rates of Percutaneous Coronary Revascularization for Acute Coronary Syndromes Associated with the COVID-19 Outbreak
- Author
-
Raffaele Piccolo, Dario Bruzzese, Ciro Mauro, Antonio Aloia, Cesare Baldi, Marco Boccalatte, Giuseppe Bottiglieri, Carlo Briguori, Gianluca Caiazzo, Paolo Calabrò, Maurizio Cappelli-Bigazzi, Ciro De Simone, Emilio Di Lorenzo, Paolo Golino, Vittorio Monda, Rocco Perrotta, Gaetano Quaranta, Enrico Russolillo, Marino Scherillo, Tullio Tesorio, Bernardino Tuccillo, Giuseppe Valva, Bruno Villari, Giuseppe Tarantini, Attilio Varricchio, Giovanni Esposito, Marisa Avvedimento, Renato Maria Bianchi, Stefano Capobianco, Gerardo Carpinella, Mario Crisci, Luca Esposito, Luciano Fattore, Luigi Fimiani, Dario Formigli, Marco Golino, Eugenio Laurenzano, Attilio Leone, Fabio Magliulo, Tullio Niglio, Roberto Padalino, Fabio Pastore, Federica Serino, Fortunato Scotto Di Uccio, Gabriella Visconti, Piccolo, Raffaele, Bruzzese, Dario, Mauro, Ciro, Aloia, Antonio, Baldi, Cesare, Boccalatte, Marco, Bottiglieri, Giuseppe, Briguori, Carlo, Caiazzo, Gianluca, Calabrò, Paolo, Cappelli-Bigazzi, Maurizio, De Simone, Ciro, Di Lorenzo, Emilio, Golino, Paolo, Monda, Vittorio, Perrotta, Rocco, Quaranta, Gaetano, Russolillo, Enrico, Scherillo, Marino, Tesorio, Tullio, Tuccillo, Bernardino, Valva, Giuseppe, Villari, Bruno, Tarantini, Giuseppe, Varricchio, Attilio, and Esposito, Giovanni
- Subjects
Acute coronary syndrome ,medicine.medical_specialty ,Percutaneous ,medicine.medical_treatment ,Population ,Disease Outbreaks ,acute coronary syndrome ,Betacoronavirus ,Physiology (medical) ,Pandemic ,Epidemiology ,Correspondence ,Research Letter ,Humans ,Medicine ,Viral ,education ,Pandemics ,education.field_of_study ,biology ,business.industry ,SARS-CoV-2 ,percutaneous coronary intervention ,Outbreak ,Percutaneous coronary intervention ,COVID-19 ,Acute Coronary Syndrome ,Coronavirus Infections ,Percutaneous Coronary Intervention ,Pneumonia, Viral ,Population Surveillance ,Pneumonia ,biology.organism_classification ,medicine.disease ,Emergency medicine ,epidemiology ,Cardiology and Cardiovascular Medicine ,business - Published
- 2020
122. Percutaneous coronary intervention versus coronary artery bypass grafting for left main disease according to age: A meta-analysis
- Author
-
De Filippo, Ovidio, Di Franco, Antonino, Improta, Riccardo, Di Pietro, Gianluca, Leone, Attilio, Pecoraro, Martina, Meynet, Pierre, Carbone, Maria Luisa, Di Lorenzo, Emilio, Bruno, Francesco, Demetres, Michelle, Carmeci, Antonino, Conrotto, Federico, Mancone, Massimo, De Ferrari, Gaetano Maria, Gaudino, Mario, and D'Ascenzo, Fabrizio
- Full Text
- View/download PDF
123. Update of the position document of the Italian Society of Interventional Cardiology (SICI-GISE) on the minimum requirements for hospitals and operators performing procedures of a transcatheter implantation of aortic valve prostheses
- Author
-
Tarantini, G., Esposito, G., Musumeci, G., Fraccaro, C., Franzone, A., Castiglioni, B., La Manna, A., Limbruno, U., Marchese, A., Mauro, C., Rigattieri, S., Tarantino, F., Gandolfo, C., Santoro, G., Violini, R., Airoldi, F., Albiero, R., Balbi, M., Baralis, G., Bartorelli, A.L., Bedogni, F., Benassi, A., Berni, A., Bonzani, G., Bortone, A.S., Braito, G., Briguori, C., Brscic, E., Calabrò, P., Calchera, I., Bigazzi, M.C., Caprioglio, F., Castriota, F., Cernetti, C., Cicala, C., Cioffi, P., Colombo, A., Colombo, V., Contegiacomo, G., Cremonesi, A., D'Amico, M., De Benedictis, M., De Leo, A., Di Biasi, M., Di Girolamo, D., Di Lorenzo, E., Di Mario, C., Dominici, M., Ettori, F., Ferrario, M., Fioranelli, M., Fischetti, D., Gabrielli, G., Giordano, A., Giudice, P., Greco, C., Indolfi, C., Leonzi, O., Lettieri, C., Loi, B., Maddestra, N., Marchionni, N., Marrozzini, C., Medda, M., Missiroli, B., Luigi, M., Oreglia, J.A., Palmieri, C., Pantaleo, P., Paparoni, S.R., Parodi, G., Petronio, A.S., Piatti, L., Piccaluga, E., Pierli, C., Perkan, A., Pitì, A., Poli, A., Ramondo, A.B., Reale, M.A., Reimers, B., Ribichini, F.L., Rosso, R., Saccà, S., Sacra, C., Santarelli, A., Sardella, G., Satullo, G., Scalise, F., Siviglia, M., Spedicato, L., Stabile, A., Tamburino, C., Tesorio, T.N.M., Tolaro, S., Tomai, F., Trani, C., Valenti, R., Valsecchi, O., Valva, G., Varbella, F., Vigna, C., Vignali, L., Berti, S., Tarantini, Giuseppe, Esposito, Giovanni, Musumeci, Giuseppe, Fraccaro, Chiara, Franzone, Anna, Castiglioni, Battistina, La Manna, Alessio, Limbruno, Ugo, Marchese, Alfredo, Mauro, Ciro, Rigattieri, Stefano, Tarantino, Fabio, Gandolfo, Caterina, Santoro, Gennaro, Violini, Roberto, Airoldi, Flavio, Albiero, Remo, Balbi, Manrico, Baralis, Giorgio, Bartorelli, Antonio Luca, Bedogni, Francesco, Benassi, Alberto, Berni, Andrea, Bonzani, Giulio, Bortone, Alessandro Santo, Braito, Giuseppe, Briguori, Carlo, Brscic, Elvi, Calabrò, Paolo, Calchera, Ivan, Cappelli Bigazzi, Maurizio, Caprioglio, Francesco, Castriota, Fausto, Cernetti, Carlo, Cicala, Cinzia, Cioffi, Paolo, Colombo, Antonio, Colombo, Virgilio, Contegiacomo, Gaetano, Cremonesi, Alberto, D'Amico, Maurizio, De Benedictis, Mauro, De Leo, Alessandro, Di Biasi, Maurizio, Di Girolamo, Domenico, Di Lorenzo, Emilio, Di Mario, Carlo, Dominici, Marcello, Ettori, Federica, Ferrario, Maurizio, Fioranelli, Massimo, Fischetti, Dionigi, Gabrielli, Gabriele, Giordano, Arturo, Giudice, Pietro, Greco, Cesare, Indolfi, Ciro, Leonzi, Ornella, Lettieri, Corrado, Loi, Bruno, Maddestra, Nicola, Marchionni, Niccolò, Marrozzini, Cinzia, Medda, Massimo, Missiroli, Bindo, Luigi, My, Oreglia, Jacopo Andrea, Palmieri, Cataldo, Pantaleo, Paolo, Paparoni, Saro Roberto, Parodi, Guido, Petronio, Anna Sonia, Piatti, Luigi, Piccaluga, Emanuela, Pierli, Carlo, Perkan, Andrea, Pitì, Antonino, Poli, Arnaldo, Ramondo, Angelo Bruno, Reale, Maurizio Alessandro, Reimers, Bernhard, Ribichini, Flavio Luciano, Rosso, Roberta, Saccà, Salvatore, Sacra, Cosimo, Santarelli, Andrea, Sardella, Gennaro, Satullo, Gaetano, Scalise, Filippo, Siviglia, Massimo, Spedicato, Leonardo, Stabile, Amerigo, Tamburino, Corrado, Tesorio, Tullio Nicola Maria, Tolaro, Salvatore, Tomai, Fabrizio, Trani, Carlo, Valenti, Renato, Valsecchi, Orazio, Valva, Giuseppe, Varbella, Ferdinando, Vigna, Carlo, Vignali, Luigi, and Berti, Sergio
- Subjects
Transcatheter aortic valve implantation ,Institutions ,Operators ,Requirements ,Training ,Cardiology and Cardiovascular Medicine ,Requirement ,Institution ,Operator ,Settore MED/11 - Malattie dell'Apparato Cardiovascolare - Abstract
Transcatheter aortic valve implantation (TAVI) has revolutionized the management of patients with symptomatic severe aortic stenosis and has become the standard of care for inoperable patients and the preferred therapy for those at increased surgical risk with peculiar clinical and anatomic features. Technology advances, growing experience and accumulating data prompted the update of the 2011 Italian Society of Interventional Cardiology (SICI-GISE) position paper on institutional and operator requirements to perform TAVI. The main objective of this document is to provide a guidance to assess the potential of institutions and operators to initiate and maintain an efficient TAVI program. Transcatheter aortic valve implantation (TAVI) has revolutionized the management of patients with symptomatic severe aortic stenosis and has become the standard of care for inoperable patients and the preferred therapy for those at increased surgical risk with peculiar clinical and anatomic features. Technology advances, growing experience and accumulating data prompted the update of the 2011 Italian Society of Interventional Cardiology (SICI-GISE) position paper on institutional and operator requirements to perform TAVI. The main objective of this document is to provide a guidance to assess the potential of institutions and operators to initiate and maintain an efficient TAVI program.
- Published
- 2018
124. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial
- Author
-
Marco Valgimigli, Enrico Frigoli, Sergio Leonardi, Pascal Vranckx, Martina Rothenbühler, Matteo Tebaldi, Ferdinando Varbella, Paolo Calabrò, Stefano Garducci, Paolo Rubartelli, Carlo Briguori, Giuseppe Andó, Maurizio Ferrario, Ugo Limbruno, Roberto Garbo, Paolo Sganzerla, Filippo Russo, Marco Nazzaro, Alessandro Lupi, Bernardo Cortese, Arturo Ausiello, Salvatore Ierna, Giovanni Esposito, Giuseppe Ferrante, Andrea Santarelli, Gennaro Sardella, Nicoletta de Cesare, Paolo Tosi, Arnoud van 't Hof, Elmir Omerovic, Salvatore Brugaletta, Stephan Windecker, Dik Heg, Peter Jüni, Gianluca Campo, Lucia Uguccioni, Corrado Tamburino, Patrizia Presbitero, Dennis Zavalloni-Parenti, Fabio Ferrari, Roberto Ceravolo, Fabio Tarantino, Giampaolo Pasquetto, Gavino Casu, Stefano Mameli, Maria Letizia Stochino, Pietro Mazzarotto, Alberto Cremonesi, Francesco Saia, Giovanni Saccone, Fabio Abate, Andrea Picchi, Roberto Violini, Salvatore Colangelo, Giacomo Boccuzzi, Vincenzo Guiducci, Carlo Vigna, Antonio Zingarelli, Andrea Gagnor, Tiziana Zaro, Simone Tresoldi, Pietro Vandoni, Marco Contarini, Armando Liso, Antonio Dellavalle, Salvatore Curello, Fabio Mangiacapra, Rosario Evola, Cataldo Palmieri, Camillo Falcone, Francesco Liistro, Manuela Creaco, Antonio Colombo, Alaide Chieffo, Andrea Perkan, Stefano De Servi, Dionigi Fischetti, Stefano Rigattieri, Alessandro Sciahbasi, Edoardo Pucci, Enrico Romagnoli, Claudio Moretti, Luciano Moretti, Raffaele De Caterina, Marcello Caputo, Marco Zimmarino, Ezio Bramucci, Emilio Di Lorenzo, Maurizio Turturo, Roberto Bonmassari, Carlo Penzo, Bruno Loi, Ciro Mauro, Anna Sonia Petronio, Gabriele Gabrielli, Antonio Micari, Flavia Belloni, Francesco Amico, Marco Comeglio, Claudio Fresco, Isala Klinieken, Nicolas Van Mieghem, Roberto Diletti, Evelyn Regar, Manel Sabaté, Joan Antoni Gómez Hospital, José Francisco Díaz Fernández, Vicente Mainar, Jose Maria de la Torre Hernandez, Valgimigli, Marco, Frigoli, Enrico, Leonardi, Sergio, Vranckx, Pascal, Rothenbühler, Martina, Tebaldi, Matteo, Varbella, Ferdinando, Calabrò, Paolo, Garducci, Stefano, Rubartelli, Paolo, Briguori, Carlo, Andó, Giuseppe, Ferrario, Maurizio, Limbruno, Ugo, Garbo, Roberto, Sganzerla, Paolo, Russo, Filippo, Nazzaro, Marco, Lupi, Alessandro, Cortese, Bernardo, Ausiello, Arturo, Ierna, Salvatore, Esposito, Giovanni, Ferrante, Giuseppe, Santarelli, Andrea, Sardella, Gennaro, de Cesare, Nicoletta, Tosi, Paolo, van 't Hof, Arnoud, Omerovic, Elmir, Brugaletta, Salvatore, Windecker, Stephan, Heg, Dik, Jüni, Peter, Cardiologie, RS: CARIM - R2.01 - Clinical atrial fibrillation, MUMC+: MA Med Staf Spec Cardiologie (9), Campo, Gianluca, Uguccioni, Lucia, Tamburino, Corrado, Presbitero, Patrizia, Zavalloni-Parenti, Denni, Ferrari, Fabio, Ceravolo, Roberto, Tarantino, Fabio, Pasquetto, Giampaolo, Casu, Gavino, Mameli, Stefano, Stochino, Maria Letizia, Mazzarotto, Pietro, Cremonesi, Alberto, Saia, Francesco, Saccone, Giovanni, Abate, Fabio, Picchi, Andrea, Violini, Roberto, Colangelo, Salvatore, Boccuzzi, Giacomo, Guiducci, Vincenzo, Vigna, Carlo, Zingarelli, Antonio, Gagnor, Andrea, Zaro, Tiziana, Tresoldi, Simone, Vandoni, Pietro, Contarini, Marco, Liso, Armando, Dellavalle, Antonio, Curello, Salvatore, Mangiacapra, Fabio, Evola, Rosario, Palmieri, Cataldo, Falcone, Camillo, Liistro, Francesco, Creaco, Manuela, Colombo, Antonio, Chieffo, Alaide, Perkan, Andrea, De Servi, Stefano, Fischetti, Dionigi, Rigattieri, Stefano, Sciahbasi, Alessandro, Pucci, Edoardo, Romagnoli, Enrico, Moretti, Claudio, Moretti, Luciano, De Caterina, Raffaele, Caputo, Marcello, Zimmarino, Marco, Bramucci, Ezio, Di Lorenzo, Emilio, Turturo, Maurizio, Bonmassari, Roberto, Penzo, Carlo, Loi, Bruno, Mauro, Ciro, Petronio, Anna Sonia, Gabrielli, Gabriele, Micari, Antonio, Belloni, Flavia, Amico, Francesco, Comeglio, Marco, Fresco, Claudio, Klinieken, Isala, Van Mieghem, Nicola, Diletti, Roberto, Regar, Evelyn, Sabaté, Manel, Gómez Hospital, Joan Antoni, Díaz Fernández, José Francisco, Mainar, Vicente, and de la Torre Hernandez, Jose Maria
- Subjects
Male ,Prasugrel ,medicine.medical_treatment ,MONOTHERAPY ,Myocardial Infarction ,030204 cardiovascular system & hematology ,Coronary Angiography ,ANGIOGRAPHY ,law.invention ,0302 clinical medicine ,Randomized controlled trial ,law ,Bivalirudin ,ARTERY-DISEASE ,030212 general & internal medicine ,Myocardial infarction ,610 Medicine & health ,Medicine (all) ,SITE ,2017 ESC ,PCI ,General Medicine ,Hirudins ,Middle Aged ,Clopidogrel ,Recombinant Proteins ,Prosthesis Failure ,Stroke ,Femoral Artery ,Acute Coronary Syndrome ,Aged ,Anticoagulants ,Antithrombins ,Female ,Hemorrhage ,Heparin ,Humans ,Mortality ,Peptide Fragments ,Percutaneous Coronary Intervention ,Perioperative Care ,Platelet Glycoprotein GPIIb-IIIa Complex ,Stents ,Radial Artery ,Cardiology ,Ticagrelor ,INTERVENTION ,medicine.drug ,Acute coronary syndrome ,medicine.medical_specialty ,ACUTE MYOCARDIAL-INFARCTION ,03 medical and health sciences ,Internal medicine ,medicine ,METAANALYSIS ,business.industry ,Percutaneous coronary intervention ,medicine.disease ,business - Abstract
Summary Background The Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of radial versus femoral access and of bivalirudin versus unfractionated heparin with optional glycoprotein IIb/IIIa inhibitors in patients with the whole spectrum of acute coronary syndrome undergoing invasive management. Here we describe the prespecified final 1-year outcomes of the entire programme. Methods MATRIX was a programme of three nested, randomised, multicentre, open-label, superiority trials in patients with acute coronary syndrome in 78 hospitals in Italy, the Netherlands, Spain, and Sweden. Patients with ST-elevation myocardial infarction were simultaneously randomly assigned (1:1) before coronary angiography to radial or femoral access and to bivalirudin, with or without post-percutaneous coronary intervention infusion or unfractionated heparin (one-step inclusion). Patients with non-ST-elevation acute coronary syndrome were randomly assigned (1:1) before coronary angiography to radial or femoral access and, only if deemed eligible to percutaneous coronary intervention after angiography (two-step inclusion), entered the antithrombin type and treatment duration programmes. Randomisation sequences were computer generated, blocked, and stratified by intended new or current use of P2Y12 inhibitor (clopidogrel vs ticagrelor or prasugrel), and acute coronary syndrome type (ST-elevation myocardial infarction, troponin-positive, or troponin-negative non-ST-elevation acute coronary syndrome). Bivalirudin was given as a bolus of 0·75 mg/kg, followed immediately by an infusion of 1·75 mg/kg per h until completion of percutaneous coronary intervention. Heparin was given at 70–100 units per kg in patients not receiving glycoprotein IIb/IIIa inhibitors, and at 50–70 units per kg in patients receiving glycoprotein IIb/IIIa inhibitors. Clinical follow-up was done at 30 days and 1 year. Co-primary outcomes for MATRIX access and MATRIX antithrombin type were major adverse cardiovascular events, defined as the composite of all-cause mortality, myocardial infarction, or stroke up to 30 days; and net adverse clinical events, defined as the composite of non-coronary artery bypass graft-related major bleeding, or major adverse cardiovascular events up to 30 days. The primary outcome for MATRIX treatment duration was the composite of urgent target vessel revascularisation, definite stent thrombosis, or net adverse clinical events up to 30 days. Analyses were done according to the intention-to-treat principle. This trial is registered with ClinicalTrials.gov, number NCT01433627. Findings Between Oct 11, 2011, and Nov 7, 2014, we randomly assigned 8404 patients to receive radial (4197 patients) or femoral (4207 patients) access. Of these 8404 patients, 7213 were included in the MATRIX antithrombin type study and were randomly assigned to bivalirudin (3610 patients) or heparin (3603 patients). Patients assigned to bivalirudin were included in the MATRIX treatment duration study, and were randomly assigned to post-procedure infusion (1799 patients) or no post-procedure infusion (1811 patients). At 1 year, major adverse cardiovascular events did not differ between patients assigned to radial access compared with those assigned to femoral access (14·2% vs 15·7%; rate ratio 0·89, 95% CI 0·80–1·00; p=0·0526), but net adverse clinical events were fewer with radial than with femoral access (15·2% vs 17·2%; 0·87, 0·78–0·97; p=0·0128). Compared with heparin, bivalirudin was not associated with fewer major adverse cardiovascular (15·8% vs 16·8%; 0·94, 0·83–1·05; p=0·28) or net adverse clinical events (17·0% vs 18·4%; 0·91, 0·81–1·02; p=0·10). The composite of urgent target vessel revascularisation, stent thrombosis, or net adverse clinical events did not differ with or without post-procedure bivalirudin infusion (17·4% vs 17·4%; 0·99, 0·84–1·16; p=0·90). Interpretation In patients with acute coronary syndrome, radial access was associated with lower rates of net adverse clinical events compared with femoral access, but not major adverse cardiovascular events at 1 year. Bivalirudin with or without post-procedure infusion was not associated with lower rates of major adverse cardiovascular events or net adverse clinical events. Radial access should become the default approach in acute coronary syndrome patients undergoing invasive management. Funding Italian Society of Invasive Cardiology, The Medicines Company, Terumo, amd Canada Research Chairs Programme.
- Published
- 2018
125. Best Practices for Using Order-Based Modal Analysis for Industrial Applications
- Author
-
Francesco Marulo, Emilio Di Lorenzo, Simone Manzato, Wim Desmet, Bart Peeters, DI LORENZO, Emilio, Manzato, Simone, Peeters, Bart, Marulo, Francesco, and Desmet, Wim
- Subjects
Operational Modal Analysis ,Tachometer ,Commercial software ,Modal ,Computer science ,Modal analysis ,Context (language use) ,Control engineering ,Instrumentation (computer programming) ,Order tracking - Abstract
The Order-Based Modal Analysis (OBMA) technique shows to be very powerful for identifying the modal parameters in operational conditions in case of rotating machineries during transient operations. The main idea behind the method is that instead of estimating the spectra and apply Operational Modal Analysis (OMA) by using them, the so-called orders can be extracted and used as input for the OMA technique. It can be assumed that the measured responses are mainly caused by the rotational excitation. In this case, run-up and coast-down events can be assimilated to multi-sine sweep excitation in the frequency band of interest. Several studies have been performed to identify the best practice for OBMA both in terms of Order Tracking (OT) techniques and OMA techniques. Based on the boundary conditions, on the structure under-test and on the effective operational conditions a technique can be more powerful than another one. Basically there are two fundamental steps: a very good measurement of the tachometer signal and the correct extraction of the orders, both in amplitude and phase. For the first step several alternatives are possible. The sensors to be used for measuring the rotational speed are depending from both the application and the objective of the study. For this reason, several sensors can be found in the market with a huge variety of costs and performances. The best sensor can then be selected for each individual application based on the type of analysis, the accessibility of the shaft, the ease of instrumentation and the required accuracy or level of detail. For the second step, several techniques are available in commercial software and some others have been implemented in a research environment. Each of them has its own advantages and drawbacks. The final aim of the work is to provide guidelines for the correct use of the OBMA technique in an industrial context. Several cases will be shown: a locomotive cabin and a car during engine run-ups and a 3.2 MW wind turbine gearbox during controlled run-ups on a test rig.
- Published
- 2017
126. ANMCO/AIAC/SICI-GISE/SIC/SICCH Consensus Document: Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: Indications, patient selection, staff skills, organisation, and training
- Author
-
Michele Massimo Gulizia, Giuseppe Musumeci, Giancarlo Casolo, Sakis Themistoclakis, Claudio Tondo, Marco Zanobini, Christian Pristipino, Giulio Molon, Jacopo Oreglia, Roberto Di Bartolomeo, Gino Gerosa, Gian Paolo Ussia, Andrea Audo, Renato Pietro Ricci, Patrizio Mazzone, Luigi Padeletti, Gavino Casu, Michele Portoghese, Sergio Berti, Emilio Di Lorenzo, Francesco Romeo, Casu, Gavino, Gulizia, Michele Massimo, Molon, Giulio, Mazzone, Patrizio, Audo, Andrea, Casolo, Giancarlo, Di Lorenzo, Emilio, Portoghese, Michele, Pristipino, Christian, Ricci, Renato Pietro, Themistoclakis, Saki, Padeletti, Luigi, Tondo, Claudio, Berti, Sergio, Oreglia, Jacopo Andrea, Gerosa, Gino, Zanobini, Marco, Ussia, Gian Paolo, Musumeci, Giuseppe, Romeo, Francesco, and Di Bartolomeo, Roberto
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Population ,030204 cardiovascular system & hematology ,Left atrial appendage occlusion ,Dabigatran ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Edoxaban ,Internal medicine ,medicine ,030212 general & internal medicine ,Intensive care medicine ,education ,Stroke ,Rivaroxaban ,education.field_of_study ,business.industry ,Atrial fibrillation ,Articles ,medicine.disease ,3. Good health ,chemistry ,Cardiology ,Apixaban ,business ,Cardiology and Cardiovascular Medicine ,medicine.drug - Abstract
Atrial fibrillation (AF) is the most common arrhythmia and its prevalence is increasing due to the progressive aging of the population. About 20% of strokes are attributable to AF and AF patients are at five-fold increased risk of stroke. The mainstay of treatment of AF is the prevention of thromboembolic complications with oral anticoagulation therapy. Drug treatment for many years has been based on the use of vitamin K antagonists, but recently newer and safer molecules have been introduced (dabigatran etexilate, rivaroxaban, apixaban, and edoxaban). Despite these advances, many patients still do not receive adequate anticoagulation therapy because of contraindications (relative and absolute) to this treatment. Over the last decade, percutaneous closure of left atrial appendage, main site of thrombus formation during AF, proved effective in reducing thromboembolic complications, thus offering a valid medical treatment especially in patients at increased bleeding risk. The aim of this consensus document is to review the main aspects of left atrial appendage occlusion (selection and multidisciplinary assessment of patients, currently available methods and devices, requirements for centres and operators, associated therapies and follow-up modalities) having as a ground the significant evolution of techniques and the available relevant clinical data.
- Published
- 2017
127. Gear Dynamics Characterization by Using Order-Based Modal Analysis
- Author
-
Antonio Palermo, Francesco Marulo, Bart Peeters, Emilio Di Lorenzo, Wim Desmet, Simone Manzato, Andrea Dabizzi, DI LORENZO, Emilio, Palermo, Antonio, Manzato, Simone, Dabizzi, Andrea, Peeters, Bart, Desmet, Wim, and Marulo, Francesco
- Subjects
Operational Modal Analysis ,Transducer ,Modal ,Computer science ,Angular displacement ,Normal mode ,Modal analysis ,Accelerometer ,Order tracking ,Simulation - Abstract
The aim of Operational Modal Analysis (OMA) is to estimate the modal parameters of a system in operating conditions. However, for the particular case of rotating machineries during run-up/run-down, it has been demonstrated that the method shows limitations because of the so-called “end-of-order effect”. This is one of the main reasons why new techniques have been explored. The most promising one is Order-Based Modal Analysis (OBMA), which combines advanced Order Tracking techniques with Operational identification methods. To validate this technique, a measurement campaign has been performed on a gear test rig. The test rig has been heavily instrumented to perform the validation of the proposed methodology, combining several triaxial accelerometers on the support plates and gears with state-of-the-art angular position transducers. Firstly, Experimental Modal Analysis (EMA) has been performed to identify a reference dataset. Then, OBMA has been applied on several run-ups/run-downs. The results of modal analysis on orders from different Order Tracking techniques has been compared to those obtained by EMA, confirming that OBMA is capable of correctly evaluating mode shapes and natural frequencies of the gear test rig from operational data.
- Published
- 2016
- Full Text
- View/download PDF
128. Damage detection in wind turbine blades by using operational modal analysis
- Author
-
Bart Peeters, Francesco Marulo, Simone Manzato, Wim Desmet, Emilio Di Lorenzo, Giuseppe Petrone, DI LORENZO, Emilio, Petrone, Giuseppe, Manzato, S., Peeters, B., Desmet, W., and Marulo, Francesco
- Subjects
Damage detection ,Turbine blade ,Operational modal analysis, wind turbine, numerical, experimental ,020209 energy ,Mechanical Engineering ,Modal analysis ,Biophysics ,020101 civil engineering ,02 engineering and technology ,0201 civil engineering ,law.invention ,Vibration ,Operational Modal Analysis ,law ,0202 electrical engineering, electronic engineering, information engineering ,Geology ,Marine engineering - Abstract
In this paper a vibration-based approach to identify a crack in a wind turbine blade is described and demonstrated numerically and experimentally. Operational modal analysis has been performed before and after a buckling test, and vibration data, gathered from some accelerometers placed along the blade, was used to monitor the integrity of the structure, since the modal parameters are directly influenced by the physical properties of the structures. Additionally a numerical prediction has been done both with a full-scale model and with a one-dimensional model. The results show that this approach is able to estimate successfully the presence of damage and a good numerical and experimental correlation has been found. Finally, some considerations regarding the rotation of the blade in the undamaged and damaged cases have been done.
- Published
- 2016
129. Order-based modal analysis: a modal parameter estimation technique for rotating machineries
- Author
-
Di Lorenzo, E., Manzato, S., Peeters, B., Vanhollebeke, F., Desmet, W., Francesco MARULO, DI LORENZO, Emilio, Manzato, S., Peeters, B., Vanhollebeke, F., Desmet, W., and Marulo, Francesco
- Published
- 2015
130. Structural Health Monitoring Considerations on Offshore Wind Turbine Models
- Author
-
Wim Desmet, Francesco Marulo, Simone Manzato, Bart Peeters, E. Di Lorenzo, DI LORENZO, Emilio, Manzato, Simone, Peeters, Bart, Marulo, Francesco, and Desmet, Wim
- Subjects
Engineering ,Wind power ,Rotor (electric) ,Nacelle ,business.industry ,Turbine ,law.invention ,Operational Modal Analysis ,Offshore wind power ,law ,Structural health monitoring ,business ,Reference model ,Marine engineering - Abstract
The growth of wind turbines in terms of power capacity and rotor diameter size has driven the research toward new studies and ideas. Nowadays high potential sites on land have already been taken and offshore locations need to be exploited taking advantage of the stronger wind. In 2009 a 5 MW concept has been proposed by NREL in order to be considered as the reference wind turbine for the next years. In 2013 a new reference model has been introduced by DTU Wind Energy, a 10 MW wind turbine. Both offshore wind turbines have been modeled by using an aeroelastic code and several simulations have been carried on with the main objective of developing advanced health monitoring techniques. As the first step to perform Structural health Monitoring (SHM) is the identification of the most sensitive parameters to structural degradation, advanced data analysis were developed. Methods such as the Multi-Blade Coordinate (MBC) transformation and the Harmonic Power Spectrum (HPS) have been validated and combined with Operational Modal Analysis to identify the modal parameters of the turbine in operational conditions, including sensors on the tower, blades and nacelle. Once the model and analysis techniques have been validated, damages have been introduced by adding lumped masses and by reducing the blades and/or the tower stiffness. Some SHM considerations have been drawn by analyzing the so-called whirling modes. They are due to the rotation of the blades and they can be observed only after that a pre-processing technique has been applied. They have been highlighted because they seem to be very sensitive to the introduction of small damages. doi: 10.12783/SHM2015/350
- Published
- 2015
- Full Text
- View/download PDF
131. Removing the influence of rotor harmonics for improved monitoring of offshore wind turbines
- Author
-
Wout Weijtjens, Simone Manzato, Patrick Guillaume, E. Di Lorenzo, Christof Devriendt, Bart Peeters, Acoustics & Vibration Research Group, Applied Mechanics, S., Manzato, C., Devriendt, W., Weijtjen, DI LORENZO, Emilio, B., Peeter, and P., Guillaume
- Subjects
Computer science ,Rotor (electric) ,Harmonics ,Automotive engineering ,law.invention ,Operational Modal Analysis ,Identification (information) ,Offshore wind power ,operational modal analysis ,Modal ,law ,Wind Turbine ,Harmonic ,Submarine pipeline ,Physics::Atmospheric and Oceanic Physics ,Marine engineering - Abstract
© The Society for Experimental Mechanics, Inc. 2014. The ability to identify the dynamic properties of offshore wind turbines allows validating and updating numerical tools, which can be used to enhance the design. At the same time, these dynamic parameters can serve as a basis to continuously monitor the integrity of the machine. However, modal identification of turbines in operating conditions still poses some major issues, in particular in removing the rotor harmonic components, which are polluting the measured signals. This paper will present and discuss some recent developments for removing harmonic components from operational wind turbine data. The possibility to track the evolution of specific modes is compared against classical techniques such as Time Synchronous Averaging and Cepstrum, which show limitations due to rotational speed fluctuations, amplitude modulation of the harmonic components and the interaction between the harmonics and the aerodynamic loads. The methodologies are firstly presented and then applied to real data of an offshore wind turbine installed in the Belgian North Sea. The ability to identify more accurately the modal parameters will allow improving the correlation with the varying environmental conditions and provide additional input data to validate numerical models. ispartof: pages:299-312 ispartof: Dynamics of Civil Structures vol:4 pages:299-312 ispartof: IMAC 2014 location:Orlando, FL, USA date:Feb - Feb 2014 status: published
- Published
- 2014
132. Wind turbine gearbox dynamic characterization using Operational Modal Analysis
- Author
-
Sonja Goris, J. Houben, Simone Manzato, F. Vanhollebeke, E. Di Lorenzo, Bart Peeters, DI LORENZO, Emilio, S., Manzato, J., Houben, F., Vanhollebeke, S., Gori, and B., Peeters
- Subjects
Vibration ,Engineering ,Operational Modal Analysis ,Wind power ,Modal ,business.industry ,Torque ,Context (language use) ,Structural engineering ,business ,Turbine ,Marine engineering ,Dynamic testing - Abstract
© The Society for Experimental Mechanics, Inc. 2014. The aim of this paper is to characterize the dynamic behavior of a wind turbine gearbox installed on a dynamic test rig to replicate operational conditions. Wind turbines and gearboxes operate under very dynamic and complex conditions, caused by turbulent wind, fluctuations in the electricity grid etc. In those conditions, structural nonlinearities in bearings and gears cause natural frequencies to be significantly influenced by the operational conditions. To verify the dynamic response of a multi-megawatt gearbox, a comprehensive test campaign has been performed in the context of the European project ALARM at the ZF Wind Power test rig. Accelerations have been measured at more than 250 locations on the test rig and for different load levels and operating conditions. This paper focuses on the influence of the torque levels on the identified modal parameters. The acquired time histories during run-ups have been processed using different Operational Modal Analysis techniques. The aim is to provide a modal model that can be used for correlation and updating of a flexible nonlinear multibody model of the whole test rig as well as vibration levels to estimate structure-borne noise in the different operating conditions. ispartof: pages:41-52 ispartof: Topics in Modal Analysis vol:7 pages:41-52 ispartof: IMAC 2014 location:Orlando, FL, USA date:Feb - Feb 2014 status: published
- Published
- 2014
133. Dynamic characterization of wind turbine gearboxes using order-based modal analysis
- Author
-
Di Lorenzo, E., Manzato, S., Vanhollebeke, F., Goris, S., Peeters, B., Desmet, W., Francesco MARULO, DI LORENZO, Emilio, Manzato, S., Vanhollebeke, F., Goris, S., Peeters, B., Desmet, W., Marulo, Francesco, Sas, P, Moens, D, and Denayer, H
- Subjects
WIND TURBINES ,experimental modal analysis - Abstract
This paper describes an extensive measurement campaign in order to characterize gearbox vibro-acoustic behavior. The measurements have been performed at ZF Wind Power on a 13.2MW test rig facility. Accelerations have been measured at more than 250 locations on the test rig and for different load levels and operating conditions. It is important to extract from the test rig measurements those parameters which are representative for the gearbox dynamic behavior. Several techniques, such as Operational Modal Analysis (OMA) and Order Based Modal Analysis (OBMA), have been applied to the acceleration data in order to extract the modal parameters in the test rig configuration. While the first technique shows some limitations, such as the so-called "end-of-order" effect, the second technique combining advanced Order Tracking with Operational Modal Analysis, does not suffer from "end-of-order" related peaks in the spectrum and identifies only the physical poles of the system. ispartof: pages:4349-4362 ispartof: PROCEEDINGS OF INTERNATIONAL CONFERENCE ON NOISE AND VIBRATION ENGINEERING (ISMA2014) AND INTERNATIONAL CONFERENCE ON UNCERTAINTY IN STRUCTURAL DYNAMICS (USD2014) pages:4349-4362 ispartof: ISMA 2014 location:Leuven, Belgium date:Sep - Sep 2014 status: published
- Published
- 2014
134. Virtual Structural Monitoring of Wind Turbines Using Operational Modal Analysis Techniques
- Author
-
Bart Peeters, Simone Manzato, Emilio Di Lorenzo, Herman Van der Auweraer, Basu, B, DI LORENZO, Emilio, S., Manzato, B., Peeter, and H., Van der Auweraer
- Subjects
Engineering ,Wind power ,business.industry ,Mechanical Engineering ,Modal analysis ,Condition monitoring ,Control engineering ,Aeroelasticity ,Turbine ,Operational Modal Analysis ,Modal ,Mechanics of Materials ,General Materials Science ,business ,Baseline (configuration management) - Abstract
Operational Modal Analysis (OMA), also known as output-only modal analysis, allows identifying modal parameters only by using the response measurements of the structures in operational conditions when the input forces cannot be measured. This information can then be used to improve numerical models in order to monitor the operating and structural conditions of the system. This is a critical aspect both for condition monitoring and maintenance of large wind turbines, particularly in the off-shore sector where operation and maintenance represent a high percentage of total costs. Although OMA is widely applied, the wind turbine case still remains an open issue. Numerical aeroelastic models could be used, once they have been validated, to introduce virtual damages to the structures in order to analyze the generated data. Results from such models can then be used as baseline to monitor the operating and structural condition of the machine. © (2013) Trans Tech Publications. ispartof: pages:523-530 ispartof: Key Engineering Materials vol:569 pages:523-530 ispartof: DAMAS 2013 location:Dublin date:Jul - Jul 2013 status: published
- Published
- 2013
135. Virtual assessment of damage detection techniques for operational wind turbine
- Author
-
Emilio Di Lorenzo, Bart Peeters, Simone Manzato, Herman Van der Auweraer, DI LORENZO, Emilio, S., Manzato, B., Peeter, H., Van der Auweraer, Dalpiaz, G, Rubini, R, DElia, G, Cocconcelli, M, Chaari, F, Zimroz, R, Bartelmus, W, and Haddar, M
- Subjects
Operational Modal Analysis ,Wind power ,Modal ,Computer science ,business.industry ,Modal analysis ,Condition monitoring ,Aeroelasticity ,business ,Baseline (configuration management) ,Turbine ,Reliability engineering - Abstract
© Springer-Verlag Berlin Heidelberg 2014. Operational Modal Analysis (OMA), also known as output-only modal analysis, allows identifying modal parameters only by using the response measurements of the structures in operational conditions when the input forces cannot be measured. These information can then be used to improve numerical models in order to monitor the operating and structural conditions of the system. This is a critical aspect both for condition monitoring and maintenance of large wind turbines, particularly in the off-shore sector where operation and maintenance represent a high percentage of total costs. Although OMA is widely applied, the wind turbine case still remains an open issue. Numerical aeroelastic models could be used, once they have been validated, to introduce virtual damages to the structures in order to analyze the generated data. Results from such models can then be used as baseline to monitor the operating and structural condition of the machine. ispartof: pages:655-665 ispartof: Advances in Condition Monitoring of Machinery in Non-Stationary Operations vol:5 pages:655-665 ispartof: CMMNO 2013 location:Ferrara (Italy) date:May - May 2013 status: published
- Published
- 2013
136. Operational modal analysis on a wind turbine blade
- Author
-
Marulo, F., Giuseppe Petrone, D Alessandro, V., Di Lorenzo, E., Marulo, Francesco, Petrone, Giuseppe, D'Alessandro, V., DI LORENZO, Emilio, Sas, P, Moens, D, and Denayer, H
- Subjects
WIND TURBINES ,experimental modal analysis - Abstract
ispartof: pages:783-798 ispartof: PROCEEDINGS OF INTERNATIONAL CONFERENCE ON NOISE AND VIBRATION ENGINEERING (ISMA2014) AND INTERNATIONAL CONFERENCE ON UNCERTAINTY IN STRUCTURAL DYNAMICS (USD2014) pages:783-798 ispartof: ISMA 2014 location:Leuven, Belgium date:Sep - Sep 2014 status: published
137. Operational modal analysis for SHM of a wind turbine blade
- Author
-
Francesco MARULO, Petrone, G., Di Lorenzo, E., Cutolo, A., Marulo, Francesco, Petrone, Giuseppe, DI LORENZO, Emilio, and Cutolo, A.
138. Pharmacologic Treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction: Are There More Arrows on Our Bow?
- Author
-
Masarone D, Valente F, Verrengia M, Contaldi C, di Palma V, Falco L, Catapano D, and di Lorenzo E
- Abstract
Pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (PH-HFpEF) represents a frequent form of PH related to left ventricular dysfunction. The pathophysiology of PH-HFpEF is intricate, and varied and includes vascular, cardiac, and pulmonary factors that contribute synergistically to developing this clinical syndrome. Improved knowledge of the pathophysiology of PH-HFpEF has paved the way for the use of new drugs such as angiotensin receptor neprilysin inhibitors (ARNIs), non-steroidal mineral corticoid receptor antagonist (nsMRA), sodium-glucose cotransporter inhibitors (SGLT2is), levosimendan, and glucagon-like peptide 1 (GLP-1) agonists. ARNIs are a widely used drug for the treatment of PH associated with heart failure with reduced ejection fraction. They have also recently been used in PH-HFpEF patients with hemodynamic benefits that need to be confirmed in future research. Finerenone is an innovative non-steroidal mineralocorticoid receptor antagonist that exhibits notable cardioprotective and renoprotective properties in individuals suffering from chronic diabetic kidney disease. It also enhances outcomes for patients with heart failure, whether they have mildly reduced or preserved ejection fraction. Moreover, in experimental studies, finerenone has been found to lower pulmonary artery pressure, reduce muscularization, and decrease the wall thickness of pulmonary arteries. SGLT2i have revolutionized the treatment of patients with heart failure irrespective of left ventricular ejection fraction, and their treatment is also associated with an improvement in the hemodynamics profile in patients with PH-HFpEF. Levosimendan is a widely used inodilator in the treatment of acute and advanced heart failure. In addition, its use in patients with PH-HFpEF (supported by the positive effects on pulmonary hemodynamics that levosimendan exerts) has recently demonstrated hemodynamic benefit in a small phase 2 study that paved the way for phase 3 studies and the creation of an oral formulation of levosimendan. Finally, GLP1 agonists are a class of drugs that, in preliminary evidence, have shown a positive effect on cardiac hemodynamics, mainly by facilitating left ventricular unloading. These effects, along with the reduction in insulin resistance and weight loss, likely lead to beneficial outcomes for PH-HFpEF patients, especially those with obesity as a comorbidity.
- Published
- 2024
- Full Text
- View/download PDF
139. Periodic administration of levosimendan as a bridge to transplant : Potiusque sero quam nunquam.
- Author
-
Masarone D, Falco L, Caiazzo A, Marra C, and di Lorenzo E
- Published
- 2024
- Full Text
- View/download PDF
140. A case of a huge aortic pseudo-aneurysm following aortic bioprosthetic endocarditis: the key role of 3D echocardiography.
- Author
-
Sordelli C, Verde R, Fele N, Weisz SH, Severino L, Perrella A, Guarino A, Di Lorenzo E, and Severino S
- Abstract
Infective endocarditis (IE) is a life-threatening condition with high morbidity and mortality rates, making early diagnosis and intervention crucial. This report details the case of a 47-year-old male with a history of mechanical prosthetic aortic valve replacement, presenting with pyrexia and diagnosed with aortic bioprosthetic endocarditis leading to a massive aortic pseudoaneurysm. This shows that 3D transesophageal echocardiography is much more useful than regular 2D imaging for finding problems with IE, which makes surgical planning and intervention more precise.
- Published
- 2024
- Full Text
- View/download PDF
141. Percutaneous coronary intervention versus coronary artery bypass grafting for left main disease according to age: A meta-analysis.
- Author
-
De Filippo O, Di Franco A, Improta R, Di Pietro G, Leone A, Pecoraro M, Meynet P, Carbone ML, Di Lorenzo E, Bruno F, Demetres M, Carmeci A, Conrotto F, Mancone M, De Ferrari GM, Gaudino M, and D'Ascenzo F
- Abstract
Competing Interests: Conflict of Interest Statement The authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF
142. Incidental and anticipated arrhythmic diagnoses in patients with an implantable cardiac monitor.
- Author
-
Maines M, Rotondi F, Guarracini F, Esposito C, Peruzza F, Vitillo P, Kola N, Quintarelli S, Franculli F, Napoli P, Giacopelli D, Del Greco M, Di Lorenzo E, and Marini M
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Italy epidemiology, Incidence, Incidental Findings, Bradycardia diagnosis, Bradycardia epidemiology, Bradycardia therapy, Bradycardia physiopathology, Aged, 80 and over, Time Factors, Electrocardiography, Ambulatory instrumentation, Arrhythmias, Cardiac diagnosis, Arrhythmias, Cardiac therapy, Arrhythmias, Cardiac epidemiology, Arrhythmias, Cardiac physiopathology, Syncope diagnosis, Syncope etiology, Syncope epidemiology, Syncope therapy, Syncope physiopathology, Atrial Fibrillation diagnosis, Atrial Fibrillation epidemiology, Atrial Fibrillation complications, Atrial Fibrillation therapy, Atrial Fibrillation physiopathology
- Abstract
Aims: In this study, we investigated a cohort of unselected patients with various indications for an implantable cardiac monitor (ICM). Our main objectives were to determine the incidence of arrhythmic diagnoses, both anticipated and incidental in relation to the ICM indication, and to assess their clinical relevance., Methods: We examined remote monitoring transmissions from patients with an ICM at four Italian sites to identify occurrences of cardiac arrhythmias. Concurrently, we collected data on medical actions taken in response to arrhythmic findings., Results: The study included 119 patients, with a median follow-up period of 371 days. ICM indications were syncope/presyncope (46.2%), atrial fibrillation management (31.1%), and cryptogenic stroke (22.7%). In the atrial fibrillation management group, atrial fibrillation was the most common finding, with an incidence of 36% [95% confidence interval (CI) 22-55%] at 18 months. Rates of atrial fibrillation were not significantly different between patients with cryptogenic stroke and syncope/presyncope [17% (95% CI 7-40%) vs. 8% (95% CI 3-19%), P = 0.229].For patients with cryptogenic stroke, the incidence of asystole and bradyarrhythmias at 18 months was 23% (95% CI 11-45%) and 42% (95% CI 24-65%), respectively, similar to estimates obtained for patients implanted for syncope/presyncope ( P = 0.277 vs. P = 0.836).Overall, 30 patients (25.2%) required medical intervention following ICM-detected arrhythmias, predominantly involving atrial fibrillation ablation (10.9%) and medication therapy changes (10.1%)., Conclusion: In a real-life population with heterogeneous insertion indications, approximately 25% of patients received ICM-guided medical interventions within a short timeframe, including treatments for incidental findings. Common incidental arrhythmic diagnoses were bradyarrhythmias in patients with cryptogenic stroke and atrial fibrillation in patients with unexplained syncope., (Copyright © 2024 Italian Federation of Cardiology - I.F.C. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
143. A streamlined pathway for transcatheter aortic valve implantation: the BENCHMARK study.
- Author
-
Frank D, Durand E, Lauck S, Muir DF, Spence M, Vasa-Nicotera M, Wood D, Saia F, Urbano-Carrillo CA, Bouchayer D, Iliescu VA, Saint Etienne C, Leclercq F, Auffret V, Asmarats L, Di Mario C, Veugeois A, Maly J, Schober A, Nombela-Franco L, Werner N, Gómez-Hospital JA, Mascherbauer J, Musumeci G, Meneveau N, Meurice T, Mahfoud F, De Marco F, Seidler T, Leuschner F, Joly P, Collet JP, Vogt F, Di Lorenzo E, Kuhn E, Disdier VP, Hachaturyan V, Lüske CM, Rakova R, Wesselink W, Kurucova J, Bramlage P, and McCalmont G
- Subjects
- Humans, Male, Female, Aged, 80 and over, Aged, Critical Pathways, Europe epidemiology, Postoperative Complications epidemiology, Postoperative Complications prevention & control, Patient Safety, Transcatheter Aortic Valve Replacement methods, Aortic Valve Stenosis surgery, Benchmarking, Length of Stay statistics & numerical data
- Abstract
Background and Aims: There is significant potential to streamline the clinical pathway for patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of this study was to evaluate the effect of implementing BENCHMARK best practices on the efficiency and safety of TAVI in 28 sites in 7 European countries., Methods: This was a study of patients with severe symptomatic aortic stenosis (AS) undergoing TAVI with balloon-expandable valves before and after implementation of BENCHMARK best practices. Principal objectives were to reduce hospital length of stay (LoS) and duration of intensive care stay. Secondary objective was to document patient safety., Results: Between January 2020 and March 2023, 897 patients were documented prior to and 1491 patients after the implementation of BENCHMARK practices. Patient characteristics were consistent with a known older TAVI population and only minor differences. Mean LoS was reduced from 7.7 ± 7.0 to 5.8 ± 5.6 days (median 6 vs. 4 days; P < .001). Duration of intensive care was reduced from 1.8 to 1.3 days (median 1.1 vs. 0.9 days; P < .001). Adoption of peri-procedure best practices led to increased use of local anaesthesia (96.1% vs. 84.3%; P < .001) and decreased procedure (median 47 vs. 60 min; P < .001) and intervention times (85 vs. 95 min; P < .001). Thirty-day patient safety did not appear to be compromised with no differences in all-cause mortality (0.6% in both groups combined), stroke/transient ischaemic attack (1.4%), life-threatening bleeding (1.3%), stage 2/3 acute kidney injury (0.7%), and valve-related readmission (1.2%)., Conclusions: Broad implementation of BENCHMARK practices contributes to improving efficiency of TAVI pathway reducing LoS and costs without compromising patient safety., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
144. Rationale and design of the PARTHENOPE trial: A two-by-two factorial comparison of polymer-free vs biodegradable-polymer drug-eluting stents and personalized vs standard duration of dual antiplatelet therapy in all-comers undergoing PCI.
- Author
-
Piccolo R, Calabrò P, Varricchio A, Baldi C, Napolitano G, De Simone C, Mauro C, Stabile E, Caiazzo G, Tesorio T, Boccalatte M, Tuccillo B, Bottiglieri G, Russolillo E, Di Lorenzo E, Carrara G, Cassese S, Leonardi S, Biscaglia S, Costa F, McFadden E, Heg D, Franzone A, Stefanini GG, Capodanno D, and Esposito G
- Subjects
- Humans, Platelet Aggregation Inhibitors therapeutic use, Polymers, Hemorrhage chemically induced, Treatment Outcome, Drug Therapy, Combination, Drug-Eluting Stents adverse effects, Percutaneous Coronary Intervention methods, Myocardial Infarction etiology
- Abstract
Background: Over the past few decades, percutaneous coronary intervention (PCI) has undergone significant advancements as a result of the combination of device-based and drug-based therapies. These iterations have led to the development of polymer-free drug-eluting stents. However, there is a scarcity of data regarding their clinical performance. Furthermore, while various risk scores have been proposed to determine the optimal duration of dual antiplatelet therapy (DAPT), none of them have undergone prospective validation within the context of randomized trials., Design: The PARTHENOPE trial is a phase IV, prospective, randomized, multicenter, investigator-initiated, assessor-blind study being conducted at 14 centers in Italy (NCT04135989). It includes 2,107 all-comers patients with minimal exclusion criteria, randomly assigned in a 2-by-2 design to receive either the Cre8 amphilimus-eluting stent or the SYNERGY everolimus-eluting stent, along with either a personalized or standard duration of DAPT. Personalized DAPT duration is determined by the DAPT score, which accounts for both bleeding and ischemic risks. Patients with a DAPT score <2 (indicating higher bleeding than ischemic risk) receive DAPT for 3 or 6 months for chronic or acute coronary syndrome, respectively, while patients with a DAPT score ≥2 (indicating higher ischemic than bleeding risk) receive DAPT for 24 months. Patients in the standard DAPT group receive DAPT for 12 months. The trial aims to establish the noninferiority between stents with respect to a device-oriented composite end point of cardiovascular death, target-vessel myocardial infarction, or clinically-driven target-lesion revascularization at 12 months after PCI. Additionally, the trial aims to demonstrate the superiority of personalized DAPT compared to a standard approach with respect to a net clinical composite of all-cause death, any myocardial infarction, stroke, urgent target-vessel revascularization, or type 2 to 5 bleeding according to the Bleeding Academic Research Consortium criteria at 24-months after PCI., Summary: The PARTHENOPE trial is the largest randomized trial investigating the efficacy and safety of a polymer-free DES with a reservoir technology for drug-release and the first trial evaluating a personalized duration of DAPT based on the DAPT score. The study results will provide novel insights into the optimizing the use of drug-eluting stents and DAPT in patients undergoing PCI., Competing Interests: Disclosures Dr Piccolo reports personal fees from Abbott Vascular, Biotronik, Terumo, Amgen, Boehringer Ingelheim, and Daiichi-Sankyo, outside the submitted work. Dr Esposito reports personal fees from Abbott Vascular, Amgen, Boehringer Ingelheim, Edwards Lifesciences, Terumo, and Sanofi, outside the submitted work and research grants to the institution from Alvimedica, Boston Scientific, and Medtronic, outside the submitted work., (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
145. [Transcatheter approach in patients with severe aortic stenosis and concomitant severe mitral regurgitation].
- Author
-
Lanni F, Granata R, Capobianco S, and Di Lorenzo E
- Subjects
- Aortic Valve surgery, Humans, Severity of Illness Index, Stroke Volume, Treatment Outcome, Ventricular Function, Left, Aortic Valve Stenosis complications, Aortic Valve Stenosis surgery, Mitral Valve Insufficiency surgery, Transcatheter Aortic Valve Replacement
- Abstract
Patients with severe aortic valve stenosis who are candidates for transcatheter aortic valve replacement represent a high-risk population for the presence of frequent comorbidities (reduced left ventricular ejection fraction, associated valve insufficiency, right ventricular dysfunction and/or pulmonary hypertension). Aortic valve stenosis can be associated with any other valve defects but among these mitral regurgitation is the most commonly associated valve disease. The simultaneous presence of severe mitral regurgitation in patients with aortic stenosis is a negative prognostic factor, resulting in increased mortality and a high diagnostic complexity, in particular in the accuracy of the evaluation of the two valve defects and therapeutic management which, at present, are not supported by strong scientific evidence.
- Published
- 2021
- Full Text
- View/download PDF
146. Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction.
- Author
-
Chichareon P, Modolo R, Collet C, Tenekecioglu E, Vink MA, Oh PC, Ahn JM, Musto C, Díaz de la Llera LS, Cho YS, Violini R, Park SJ, Suryapranata H, Piek JJ, de Winter RJ, Wykrzykowska JJ, Spaulding C, Kang WC, Slagboom T, Hofma SH, Wijnbergen IF, Di Lorenzo E, Pijls NH, Räber L, Brugaletta S, Sabaté M, Stoll HP, Stone GW, Windecker S, Onuma Y, and Serruys PW
- Subjects
- Humans, Randomized Controlled Trials as Topic, Treatment Outcome, Drug-Eluting Stents statistics & numerical data, Percutaneous Coronary Intervention instrumentation, ST Elevation Myocardial Infarction surgery
- Abstract
Background: To date, no specific drug-eluting stent (DES) has fully proven its superiority over others in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention., Objectives: The purpose of this study was to compare the safety and efficacy of coronary artery stents in STEMI patients in a patient-level network meta-analysis., Methods: Eligible studies were dedicated randomized controlled trials comparing different stents in STEMI patients undergoing percutaneous coronary intervention with at least 12 months of clinical follow-up. Of 19 studies identified from the published data, individual patient data were collected in 15 studies with 10,979 patients representing 87.7% of patients in the overall network of evidence. The primary endpoint was the composite of cardiac death, reinfarction, or target lesion revascularization., Results: Overall, 8,487 (77.3%) of 10,979 STEMI patients were male and the mean age was 60.7 years. At a median follow-up of 3 years, compared with bare-metal stents (BMS), patients treated with paclitaxel-, sirolimus-, everolimus-, or biolimus-eluting stents had a significantly lower risk of the primary endpoint (adjusted hazard ratios [HRs]: 0.74 [95% confidence interval (CI): 0.63 to 0.88], 0.65 [95% CI: 0.49 to 0.85], 0.70 [95% CI: 0.53 to 0.91], and 0.66 [95% CI: 0.49 to 0.88], respectively). The risk of primary endpoint was not different between patients treated with BMS and zotarolimus-eluting stents (adjusted HR: 0.83 [95% CI: 0.51 to 1.38]). Among patients treated with DES, no significant difference in the risk of the primary outcome was demonstrated. Treatment with second-generation DES was associated with significantly lower risk of definite or probable stent thrombosis compared with BMS (adjusted HR: 0.61 [95% CI: 0.42 to 0.89]) and first-generation DES (adjusted HR: 0.56 [95% CI: 0.36 to 0.88])., Conclusions: In STEMI patients, DES were superior to BMS with respect to long-term efficacy. No difference in long-term efficacy and safety was observed among specific DES. Second-generation were superior to first-generation DES in reducing stent thrombosis. (Clinical Outcomes After Primary Percutaneous Coronary Intervention [PCI] Using Contemporary Drug-Eluting Stent [DES]: Evidence From the Individual Patient Data Network Meta-Analysis; CRD42018104053)., (Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
147. [Updated SICI-GISE position paper on institutional and operator requirements for transcatheter aortic valve implantation].
- Author
-
Tarantini G, Esposito G, Musumeci G, Fraccaro C, Franzone A, Castiglioni B, La Manna A, Limbruno U, Marchese A, Mauro C, Rigattieri S, Tarantino F, Gandolfo C, Santoro G, Violini R, Airoldi F, Albiero R, Balbi M, Baralis G, Bartorelli AL, Bedogni F, Benassi A, Berni A, Bonzani G, Bortone AS, Braito G, Briguori C, Brscic E, Calabrò P, Calchera I, Cappelli Bigazzi M, Caprioglio F, Castriota F, Cernetti C, Cicala C, Cioffi P, Colombo A, Colombo V, Contegiacomo G, Cremonesi A, D'Amico M, De Benedictis M, De Leo A, Di Biasi M, Di Girolamo D, Di Lorenzo E, Di Mario C, Dominici M, Ettori F, Ferrario M, Fioranelli M, Fischetti D, Gabrielli G, Giordano A, Giudice P, Greco C, Indolfi C, Leonzi O, Lettieri C, Loi B, Maddestra N, Marchionni N, Marrozzini C, Medda M, Missiroli B, My L, Oreglia JA, Palmieri C, Pantaleo P, Paparoni SR, Parodi G, Petronio AS, Piatti L, Piccaluga E, Pierli C, Perkan A, Pitì A, Poli A, Ramondo AB, Reale MA, Reimers B, Ribichini FL, Rosso R, Saccà S, Sacra C, Santarelli A, Sardella G, Satullo G, Scalise F, Siviglia M, Spedicato L, Stabile A, Tamburino C, Tesorio TNM, Tolaro S, Tomai F, Trani C, Valenti R, Valsecchi O, Valva G, Varbella F, Vigna C, Vignali L, and Berti S
- Subjects
- Aortic Valve Stenosis physiopathology, Biomedical Technology trends, Humans, Italy, Severity of Illness Index, Transcatheter Aortic Valve Replacement instrumentation, Aortic Valve Stenosis surgery, Program Development methods, Transcatheter Aortic Valve Replacement methods
- Abstract
Transcatheter aortic valve implantation (TAVI) has revolutionized the management of patients with symptomatic severe aortic stenosis and has become the standard of care for inoperable patients and the preferred therapy for those at increased surgical risk with peculiar clinical and anatomic features. Technology advances, growing experience and accumulating data prompted the update of the 2011 Italian Society of Interventional Cardiology (SICI-GISE) position paper on institutional and operator requirements to perform TAVI. The main objective of this document is to provide a guidance to assess the potential of institutions and operators to initiate and maintain an efficient TAVI program.
- Published
- 2018
- Full Text
- View/download PDF
148. [SICI-GISE commuNity CAmpania survey doNna TAVI (INCANTA): perioperative and short-term outcome of transcatheter aortic valve implantation in women].
- Author
-
Attisano T, Silverio A, Di Lorenzo E, Tesorio T, Di Girolamo D, Golino P, Giordano A, Valva G, Esposito G, Cappelli Bigazzi M, Briguori C, Monteforte I, Dialetto G, Rubino P, Vigorito F, Giudice P, and Mauro C
- Subjects
- Aged, Aged, 80 and over, Anesthesia, General statistics & numerical data, Anesthesia, Local statistics & numerical data, Equipment Design, Female, Health Care Surveys, Heart Valve Prosthesis, Humans, Italy, Length of Stay statistics & numerical data, Pacemaker, Artificial, Patient Selection, Postoperative Complications epidemiology, Retrospective Studies, Risk, Treatment Outcome, Transcatheter Aortic Valve Replacement methods
- Abstract
Background: Nowadays the prognostic role of gender as a relevant factor after transcatheter aortic valve implantation (TAVI) is still unfair, since available data in the literature are few and uneven. The aim of this survey was to collect acute and 30-day safety and efficacy clinical data in high- and intermediate-risk women, who underwent TAVI with new-generation devices, in the Campania Region., Methods: All medium and high-volume TAVI centers in Campania have been invited to fulfill an online, ad-hoc questionnaire, collecting pre-, peri- and post-procedural data concerning female patients, treated between January and December 2016., Results: 331 women (representing the 61% of the overall population treated; mean age 83 ± 7 years) underwent TAVI in the participating Campania centers. Age >80 years (72%), high surgical risk score (63%) and frailty (55%) were found to be the top three reasons for the TAVI choice. Overall, 95% of the procedures were performed by transfemoral approach with local anesthesia; the remaining 5% (16 cases) were conducted via transapical (14, 4%) and transaortic (2, 1%) accesses, under general anesthesia. Edwards Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) and Medtronic Evolut R (Medtronic Inc., Minneapolis, MN, USA) were the most frequently implanted valves (146, 44% and 132, 43%, respectively). The questioned Centers reported a mean length of hospital stay of 5.5 ± 1.1 days, 1.6 ± 0.37 of which in a cardiac care unit. The most prevalent in-hospital complication was pacemaker implantation (15%), followed by life-threatening vascular complications (3%). The 30-day VARC-2 composite endpoint occurred in 7% of cases, all-cause death in 4%, and stroke in 1%., Conclusions: This survey, the first representative of women undergoing TAVI in Campania, appears to confirm the good safety and efficacy profile of this procedure, also in the high- and intermediate-risk settings, probably favored by a prevalent use of new-generation devices and a low rate prevalence of significant patient comorbidities.
- Published
- 2017
- Full Text
- View/download PDF
149. Fractional Flow Reserve Evaluation and Chronic Kidney Disease: Analysis From a Multicenter Italian Registry (the FREAK Study).
- Author
-
Tebaldi M, Biscaglia S, Fineschi M, Manari A, Menozzi M, Secco GG, Di Lorenzo E, D'Ascenzo F, Fabbian F, Tumscitz C, Ferrari R, and Campo G
- Subjects
- Aged, Aged, 80 and over, Biomarkers blood, Cardiac Catheterization, Coronary Angiography, Coronary Stenosis physiopathology, Coronary Stenosis therapy, Creatinine blood, Female, Glomerular Filtration Rate, Humans, Italy, Kidney physiopathology, Male, Microcirculation, Middle Aged, Myocardial Revascularization, Predictive Value of Tests, Prospective Studies, Registries, Renal Insufficiency, Chronic blood, Renal Insufficiency, Chronic diagnosis, Severity of Illness Index, Vascular Resistance, Coronary Stenosis diagnosis, Fractional Flow Reserve, Myocardial, Renal Insufficiency, Chronic complications
- Abstract
Objectives: To establish if the presence of chronic kidney disease (CKD) influences fractional flow reserve (FFR) value in patients with intermediate coronary stenosis., Background: FFR-guided coronary revascularization reduces cardiac adverse events in patients with coronary artery disease. CKD impairs microcirculation and increases cardiovascular risk. Whether CKD presence may limit FFR accuracy is unknown., Methods: We used data from a multicenter prospective registry enrolling 1.004 patients undergoing FFR evaluation for intermediate stenosis. We assessed the relationship between clinical and angiographic variables and FFR measurement. CKD was defined as CrCl value ≤45 ml/min. FFR value was considered potentially flow-limiting, and therefore positive, if ≤0.80. The index of microcirculatory resistance (IMR) was calculated in 20 patients stratified according CrCl value (single-center substudy)., Results: FFR measurement was positive in 395 (39%) patients. Overall, 131 (13%) patients had CKD. Patients with CrCl ≤45 ml/min showed significantly higher FFR values as compared to the others (0.84 ± 0.07 vs. 0.81 ± 0.08, p < 0.001). Positive FFR occurrence was lower in patients with CrCl ≤45 ml/min (27% vs. 41%, p < 0.01). After multivariable analysis, diabetes (HR 1.07, 95%CI 1.008-1.13, p = 0.03), left anterior descending (HR 1.35, 95%CI 1.27-1.43, p < 0.001) and CrCl ≤45 ml/min (HR 0.92, 95%CI 0.87-0.97, p = 0.005) emerged as independent predictors of FFR measurement. Accordingly, IMR values were higher in patients with CrCl ≤45 ml/min (32 U [28245] vs. 16 U [11220], p < 0.01)., Conclusions: FFR and IMR measurements differ between CKD patients and those with normal renal function. Flow-limiting FFR is less frequent in patients with CrCl ≤45 ml/min. © 2015 Wiley Periodicals, Inc., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
150. [ANMCO/AIAC/SICI-GISE/SIC/SICCH Consensus document: Percutaneous left atrial appendage occlusion in patients with nonvalvular atrial fibrillation: indications, patient selection, competences, organization, and operator training].
- Author
-
Casu G, Gulizia MM, Molon G, Mazzone P, Audo A, Casolo G, Di Lorenzo E, Portoghese M, Pristipino C, Ricci RP, Themistoclakis S, Padeletti L, Tondo C, Berti S, Oreglia JA, Gerosa G, Zanobini M, Ussia GP, Musumeci G, Romeo F, and Di Bartolomeo R
- Subjects
- Administration, Oral, Atrial Fibrillation complications, Humans, Patient Selection, Risk Factors, Septal Occluder Device, Stroke etiology, Anticoagulants administration & dosage, Atrial Appendage surgery, Atrial Fibrillation therapy, Catheter Ablation, Fibrinolytic Agents administration & dosage, Stroke prevention & control, Thrombosis therapy
- Abstract
Atrial fibrillation (AF) is the most common arrhythmia and its prevalence is increasing due to the progressive aging of the population. About 20% of strokes are attributable to AF and AF patients are at 5-fold increased risk of stroke. The mainstay of treatment of AF is the prevention of thromboembolic complications with oral anticoagulation therapy. Drug treatment for many years has been based on the use of vitamin K antagonists, but recently newer and safer molecules have been introduced (dabigatran etexilate, rivaroxaban, apixaban and edoxaban). Despite these advances, many patients still do not receive adequate anticoagulation therapy because of contraindications (relative and absolute) to this treatment. Over the last decade, percutaneous closure of left atrial appendage, main site of thrombus formation during AF, proved effective in reducing thromboembolic complications, thus offering a valid medical treatment especially in patients at increased bleeding risk. The aim of this consensus document is to review the main aspects of left atrial appendage occlusion (selection and multidisciplinary assessment of patients, currently available methods and devices, requirements for centers and operators, associated therapies and follow-up modalities) having as a ground the significant evolution of techniques and the available relevant clinical data.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.